Form 4: Camp4 Therapeutics CFO Kelly Gold Granted Stock Options
SEC Filing Form 4
Kelly Gold, CFO of Camp4 Therapeutics, was granted stock options for 80,000 shares on April 1, 2025, according to a Form 4 filing.
Summary
- This is a Form 4 filing indicating a change in beneficial ownership for Kelly Gold, the Chief Financial Officer of Camp4 Therapeutics Corp.
- On April 1, 2025, Kelly Gold was granted stock options to purchase 80,000 shares of Camp4 Therapeutics common stock at an exercise price of $3.86 per share.
- The options vest in equal monthly installments over four years, starting from the grant date.
- Following this transaction, Kelly Gold directly owns options for 80,000 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for executives.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to work towards increasing the company's value.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The size of the grant (80,000 shares) and the vesting schedule (monthly over four years) appear to be within the typical range for CFO-level executives at similarly sized biotech companies.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock option grant |
| 04/03/2025 | Date of Form 4 filing |
| 03/31/2035 | Expiration date of the stock options |
Keywords
Form 4, stock options, beneficial ownership, Camp4 Therapeutics, Kelly Gold, CFO, equity, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.